Crossmark Global Holdings Inc. purchased a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 16,117 shares of the company's stock, valued at approximately $655,000. Crossmark Global Holdings Inc. owned approximately 0.05% of Calliditas Therapeutics AB (publ) at the end of the most recent quarter.
Calliditas Therapeutics AB (publ) Price Performance
NASDAQ CALT remained flat at $40.00 on Friday. The firm has a market capitalization of $1.19 billion, a PE ratio of -21.62 and a beta of 1.77. Calliditas Therapeutics AB has a fifty-two week low of $15.25 and a fifty-two week high of $43.00. The stock's 50 day simple moving average is $40.00 and its 200 day simple moving average is $37.02. The company has a debt-to-equity ratio of 9.44, a quick ratio of 2.59 and a current ratio of 2.69.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. Calliditas Therapeutics AB (publ) had a negative return on equity of 212.04% and a negative net margin of 30.18%. The firm had revenue of $52.36 million for the quarter, compared to analysts' expectations of $42.89 million. During the same period in the prior year, the business earned ($0.33) EPS. On average, sell-side analysts anticipate that Calliditas Therapeutics AB will post -0.99 earnings per share for the current year.
Calliditas Therapeutics AB (publ) Company Profile
(
Free Report)
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
Read More
Before you consider Calliditas Therapeutics AB (publ), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Calliditas Therapeutics AB (publ) wasn't on the list.
While Calliditas Therapeutics AB (publ) currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
